Tag - cell therapy

Markets

Brookline starts Heat Biologics at buy; PT $8

Brookline Capital Markets launched coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and $8 price target. The stock closed at 52 cents on July 29. Heat Biologics has cell-therapy platforms called ImPACT and...

July 30, 2019

Executive Moves

PharmaCyte appoints cellular expert, David Judd, to medical and SAB

David Judd PharmaCyte Biotech (OTCQB: PMCB) appointed David Judd to its medical and scientific advisory board. Mr. Judd has had over 30 years of experience in the research and development of cell culture materials and...

July 15, 2019

Feature

NeoStem completing enrollment in heart trial

By Len Zehr NeoStem (NASDAQ:NBS) is on track to complete enrollment later this year in a Phase 2 clinical trial of a bone marrow-derived cell therapy to treat patients for acute myocardial infarction, with a data...

October 29, 2013

Tag - cell therapy

Brookline starts Heat Biologics at buy; PT $8

PharmaCyte appoints cellular expert, David Judd, to medical and SAB

NeoStem completing enrollment in heart trial

General

More